• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

[A retrospective clinical analysis of malignant tumor associated with or secondary multiple myeloma].

作者信息

Liu X Y, Zhang H M, Lin Q D, Liu Y Z, Liu L N, Mei Z Y, Song Y P, Fang B J

机构信息

Department of Hematology, the Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, Henan Institute of Hematology, Zhengzhou 450008, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2018 Dec 14;39(12):1040-1042. doi: 10.3760/cma.j.issn.0253-2727.2018.12.015.

DOI:10.3760/cma.j.issn.0253-2727.2018.12.015
PMID:30612410
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7348224/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b3/7348224/9074dbb1e795/cjh-39-12-1040-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b3/7348224/9074dbb1e795/cjh-39-12-1040-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/35b3/7348224/9074dbb1e795/cjh-39-12-1040-g001.jpg

相似文献

1
[A retrospective clinical analysis of malignant tumor associated with or secondary multiple myeloma].与多发性骨髓瘤相关或继发的恶性肿瘤的回顾性临床分析
Zhonghua Xue Ye Xue Za Zhi. 2018 Dec 14;39(12):1040-1042. doi: 10.3760/cma.j.issn.0253-2727.2018.12.015.
2
Coffee and Green Tea Consumption and Subsequent Risk of Malignant Lymphoma and Multiple Myeloma in Japan: The Japan Public Health Center-based Prospective Study.日本咖啡和绿茶消费与恶性淋巴瘤及多发性骨髓瘤的后续发病风险：基于日本公共卫生中心的前瞻性研究
Cancer Epidemiol Biomarkers Prev. 2017 Aug;26(8):1352-1356. doi: 10.1158/1055-9965.EPI-17-0231.
3
[Pathological Characteristics of Bone Marrow in Multiple Myeloma Patients with Secondary Myelofibrosis and Their Relationship with Prognosis].[继发性骨髓纤维化的多发性骨髓瘤患者骨髓的病理特征及其与预后的关系]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2017 Aug;25(4):1080-1085. doi: 10.7534/j.issn.1009-2137.2017.04.021.
4
Plasma exchange in rapidly progressive renal failure due to multiple myeloma. A retrospective case series.多发性骨髓瘤所致快速进展性肾衰竭的血浆置换。一项回顾性病例系列研究。
Am J Nephrol. 1999;19(1):45-50. doi: 10.1159/000013424.
5
[Recommendations for early identification of damage to the skeleton by malignant processes, and for early diagnosis of multiple myeloma].[关于通过恶性病变早期识别骨骼损伤以及多发性骨髓瘤早期诊断的建议]
Vnitr Lek. 2006 Nov;52 Suppl 2:9, 11-31.
6
Multiple myeloma: an overview of diagnosis and management.多发性骨髓瘤：诊断与管理概述
Cleve Clin J Med. 1994 Jul-Aug;61(4):285-98. doi: 10.3949/ccjm.61.4.285.
7
Angiogenesis in multiple myeloma.多发性骨髓瘤中的血管生成
Chem Immunol Allergy. 2014;99:180-96. doi: 10.1159/000353312. Epub 2013 Oct 17.
8
Identification of malignant cells in multiple myeloma bone marrow with immunoglobulin VH gene probes by fluorescent in situ hybridization and flow cytometry.通过荧光原位杂交和流式细胞术，使用免疫球蛋白VH基因探针鉴定多发性骨髓瘤骨髓中的恶性细胞。
J Clin Invest. 1995 Mar;95(3):964-72. doi: 10.1172/JCI117805.
9
Osteoclast nuclei of myeloma patients show chromosome translocations specific for the myeloma cell clone: a new type of cancer-host partnership?骨髓瘤患者的破骨细胞核显示出特定于骨髓瘤细胞克隆的染色体易位：一种新型的癌症-宿主关系？
J Pathol. 2007 Jan;211(1):10-7. doi: 10.1002/path.2078.
10
A reversible defect in natural killer T cell function characterizes the progression of premalignant to malignant multiple myeloma.自然杀伤T细胞功能的可逆性缺陷是癌前多发性骨髓瘤向恶性多发性骨髓瘤进展的特征。
J Exp Med. 2003 Jun 16;197(12):1667-76. doi: 10.1084/jem.20021650. Epub 2003 Jun 9.

引用本文的文献

1
Effect of metachronous primary and secondary solid cancers in patients with multiple myeloma: a retrospective study from a single-center.多发性骨髓瘤患者异时性原发性和继发性实体癌的影响：一项单中心回顾性研究
Front Immunol. 2025 Mar 10;16:1516471. doi: 10.3389/fimmu.2025.1516471. eCollection 2025.

本文引用的文献

1
Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data.来那度胺治疗初诊多发性骨髓瘤的第二原发恶性肿瘤：一项个体患者数据的荟萃分析。
Lancet Oncol. 2014 Mar;15(3):333-42. doi: 10.1016/S1470-2045(13)70609-0. Epub 2014 Feb 11.
2
Update on second primary malignancies in multiple myeloma: a focused review.多发性骨髓瘤中第二原发恶性肿瘤的研究进展：重点综述。
Leukemia. 2014 Jul;28(7):1423-6. doi: 10.1038/leu.2014.22. Epub 2014 Jan 14.
3
Multiple myeloma and other malignancies: a pilot study from the Houston VA.
多发性骨髓瘤及其他恶性肿瘤：来自休斯顿退伍军人事务部的一项初步研究。
Clin Lymphoma Myeloma Leuk. 2014 Apr;14(2):102-6. doi: 10.1016/j.clml.2013.10.006. Epub 2013 Nov 15.
4
[Current status and challenges in the treatment of multiple myeloma in China].[中国多发性骨髓瘤治疗的现状与挑战]
Zhonghua Xue Ye Xue Za Zhi. 2013 Apr;34(4):281-2. doi: 10.3760/cma.j.issn.0253-2727.2013.04.001.
5
A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma.一项硼替佐米再治疗复发多发性骨髓瘤患者的前瞻性国际 2 期研究。
Br J Haematol. 2013 Mar;160(5):649-59. doi: 10.1111/bjh.12198. Epub 2013 Jan 7.
6
Second primary malignancies after autologous hematopoietic cell transplantation for multiple myeloma.自体造血细胞移植治疗多发性骨髓瘤后的第二原发性恶性肿瘤。
Biol Blood Marrow Transplant. 2013 Feb;19(2):260-5. doi: 10.1016/j.bbmt.2012.09.023. Epub 2012 Oct 13.
7
Second malignancies in total therapy 2 and 3 for newly diagnosed multiple myeloma: influence of thalidomide and lenalidomide during maintenance.新诊断多发性骨髓瘤的总治疗 2 和 3 中的第二恶性肿瘤：维持治疗期间沙利度胺和来那度胺的影响。
Blood. 2012 Aug 23;120(8):1597-600. doi: 10.1182/blood-2012-04-421883. Epub 2012 Jun 6.
8
A review of second primary malignancy in patients with relapsed or refractory multiple myeloma treated with lenalidomide.来那度胺治疗复发/难治性多发性骨髓瘤患者的第二原发性恶性肿瘤回顾。
Blood. 2012 Mar 22;119(12):2764-7. doi: 10.1182/blood-2011-08-373514. Epub 2012 Feb 9.
9
Second malignancies after multiple myeloma: from 1960s to 2010s.多发性骨髓瘤后的第二恶性肿瘤：从 20 世纪 60 年代到 21 世纪 10 年代。
Blood. 2012 Mar 22;119(12):2731-7. doi: 10.1182/blood-2011-12-381426. Epub 2012 Feb 6.
10
Myeloma and second primary cancers.骨髓瘤与第二原发性癌症。
N Engl J Med. 2011 Dec 8;365(23):2241-2. doi: 10.1056/NEJMc1111010.